secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001737287-22-000081
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial
--------------------------------------------------------------------------------

- Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.
- Cash & investments $637M at Sep 30; 2022 cash burn guidance <$250M.
- Initiated ALPHA2 Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma.
- R&D Showcase on Nov 29, 2022 to feature updated CD19 and BCMA data.
- FY 2022 GAAP operating expenses slightly below prior $360M-$390M guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/0001737287-22-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/allo-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer